Emerging drugs for mesothelioma

Bibliography

• BRITTON M: The epidemiology of mesothelioma. Semin. Oncol. (2002) 29:18-25.
   PubMed Web of Science ®Google Scholar
• HODGSON JT, DARNTON A: The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann. Occup. Hyg. (2000) 44:565-601.
   PubMed Web of Science ®Google Scholar
• Mesothelioma occupation statistics: male and female deaths aged 16 – 74 in Great Britain, 1980 – 2000 (excluding 1981). Health and Safety Executive Publications, Merseyside, England, UK (2003).
   Google Scholar
• CARBONE M, KRATZKE RA, TESTA JR: The pathogenesis of mesothelioma. Semin. Oncol. (2002) 29:2-17.
   PubMed Web of Science ®Google Scholar
• CARBONE M, PASS HI, RIZZO P et al.: Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene (1994) 9:1781-1790.
   PubMed Web of Science ®Google Scholar
• MOSSMAN BT, GRUENERT DC: SV40, growth factors, and mesothelioma: another piece of the puzzle. Am. J. Respir. Cell. Mol. Biol. (2002) 26:167-170.
   PubMed Web of Science ®Google Scholar
• PETO J, DECARLI A, LA VECCHIA C, LEVI F, NEGRI E: The European mesothelioma epidemic. Br. J. Cancer (1999) 79(3-4):666-672.
   PubMed Web of Science ®Google Scholar
• PRICE B: Analysis of current trends in United States mesothelioma incidence. Am. J. Epidemiol. (1997) 145(3):211-218.
   PubMed Web of Science ®Google Scholar
• MONTANARO F, BRAY F, GENNARO V et al.: Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control (2003) 14:791-803.
   PubMed Web of Science ®Google Scholar
• BRITISH THORACIC SOCIETYSTANDARDS OF CARE COMMITTEE: Statement on malignant mesothelioma in the United Kingdom. Thorax (2001) 56:250-256.
   PubMed Web of Science ®Google Scholar
• LEIGH J, DAVIDSON P, HENDRIE L, BERRY D: Malignant mesothelioma in Australia, 1945-2000. Am. J. Ind. Med. (2002) 41:188-201.
   PubMed Web of Science ®Google Scholar
• ROBINSON BW, LAKE RA: Advances in malignant mesothelioma. N. Engl. J. Med. (2005) 353:1591-1603.
   PubMed Web of Science ®Google Scholar
• SEGAL A, WHITAKER D, HENDERSON D, SHILKIN K: Pathology of mesothelioma. In: Mesothelioma. Robinson BW, Chahinian AP (Eds), Martin Dunitz, London, UK (2002):143-184.
   Google Scholar
• WANG ZJ, REDDY GP, GOTWAY MB et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics (2004) 24:105-119.
   PubMed Web of Science ®Google Scholar
• HERNDON JE, GREEN MR, CHAINIAN AP et al.: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 113:723-731.
   PubMed Web of Science ®Google Scholar
• EDWARDS JG, ABRAMS KR, LEVERMENT JN, SPYT TJ, WALLER DA, O’BYRNE KJ: Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax (2000) 55:731-735.
   PubMed Web of Science ®Google Scholar
• O’BYRNE KJ, EDWARDS JG, WALLER DA: Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer (2004) 45(S1):S45-S48.
   Web of Science ®Google Scholar
• FLORES RM: The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer (2005) 49(S1):27-32.
   PubMed Web of Science ®Google Scholar
• CERESOLI GL, CHITI A, ZUCALI PA et al.: Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J. Clin. Oncol. (2006) 24(28):4587-4593.
   PubMed Web of Science ®Google Scholar
• RUSCH VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest (1995) 108:1122-1128.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, MARTIN-UCAR A, PILLING JE, EDWARDS JG, O’BYRNE KJ, WALLER DA: The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann. Thorac. Surg. (2004) 78:245-252.
   PubMed Web of Science ®Google Scholar
• WALLER DA: The role of surgery in diagnosis and treatment of malignant pleural mesothelioma. Curr. Opin. Oncol. (2003) 15:139-143.
   PubMed Web of Science ®Google Scholar
• PASS HI, KRANDA K, TEMECK BK, FEUERSTEIN I, STEINBERG SM: Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann. Surg. Oncol. (1997) 4:215-222.
   PubMed Web of Science ®Google Scholar
• BALL DL, CRUICKSHANK DG: The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am. J. Clin. Oncol. (1990) 13:4-9.
   PubMed Web of Science ®Google Scholar
• BOUTIN C, REY F, VIALLAT JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest (1995) 108:754-758.
   PubMed Web of Science ®Google Scholar
• AHAMAD C, STEVENS CW, SMYTHE WR et al.: Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. (2003) 9:476-484.
   PubMed Web of Science ®Google Scholar
• RICE W, ADELSTEIN DJ, KIRBY TJ et al.: Aggressive multimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. (1994) 58:24-29.
   PubMed Web of Science ®Google Scholar
• FLORES RM: Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan–Kettering experience. Lung Cancer (2005) 49:S71-S74.
   PubMed Web of Science ®Google Scholar
• JANNE PA: Chemotherapy for malignant pleural mesothelioma. Clin. Lung Cancer (2003) 5:98-106.
   PubMedGoogle Scholar
• ELLIS P, DAVIES AM, HAYNES AE, LLOYD NS: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J. Thor. Oncol. (2006) 1:591-601.
   PubMed Web of Science ®Google Scholar
• ZIDAR BL, GREEN S, PIERCE HI, ROACH RW, BALCERZAK SP, MILITELLO L: A Phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest. New Drugs (1988) 6:223-226.
   PubMed Web of Science ®Google Scholar
• SORENSEN PG, BACH F, BORK E, HANSEN HH: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat. Rep. (1985) 69:1431-1432.
   PubMedGoogle Scholar
• SOLHEIM OP, SAETER G, FINNANGER AM et al.: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a Phase II study. Br. J. Cancer (1992) 65:956-960.
   PubMed Web of Science ®Google Scholar
• VOGELZANG NJ, WEISSMAN LB, HERNDON JE II et al.: Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study. J. Clin. Oncol. (1994) 12:1436-1442.
   Google Scholar
• VAN MEERBEECK J, DEBRUYNE C, VAN ZANDWIJK N et al.: Paclitaxel for malignant pleural mesothelioma: a Phase II study of the EORTC Lung Cancer Cooperative Group. Br. J. Cancer (1996) 74:961-963.
   PubMed Web of Science ®Google Scholar
• BERGHMANS T, PAESMANS M, LALAMI Y et al.: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer (2002) 38:111-121.
   PubMed Web of Science ®Google Scholar
• TOMEK S, EMRI S, KREJCY K, MANEGOLD C: Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br. J. Cancer (2003) 88:167-174.
   PubMed Web of Science ®Google Scholar
• STEELE JP, O’DOHERTY CA, SHAMASH J et al.: Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann. Oncol. (2001) 12:497-499.
   PubMed Web of Science ®Google Scholar
• VAN MEERBEECK JP, BAAS P, DEBRUYNE C et al.: A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer (1999) 85:2577-2582.
   PubMed Web of Science ®Google Scholar
• BYRNE MJ, DAVIDSON JA, MUSK AW et al.: Cisplatin and gemcitabine treatment for malignant mesothelioma: a Phase II study. J. Clin. Oncol. (1999) 17:25-30.
   PubMed Web of Science ®Google Scholar
• VAN HAARST JM, BAAS P, MANEGOLD CH et al. Multicentre Phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br. J. Cancer (2002) 86:342-345.
   PubMed Web of Science ®Google Scholar
• MIKULSK SM, COSTANZI JJ, VOGELZANG NJ et al.: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. (2002) 20:274-281.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ID, ZHAO R: Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin. Oncol. (2002) 29(Suppl. 18):3-17.
   PubMed Web of Science ®Google Scholar
• SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:1556-1561.
   PubMed Web of Science ®Google Scholar
• VOGELZANG MJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:2636-2644.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, TAYLOR GA, GIBSON W et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res. (1991) 51:5579-5586.
   PubMed Web of Science ®Google Scholar
• BAAS P, ARDIZZONI A, GROSSI F et al.: EORTC Lung Cancer Group: the activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: An EORTC Phase II study (08992). Eur. J. Cancer (2003) 39:353-357.
   PubMed Web of Science ®Google Scholar
• FIZAZI K, DOUBRE H, LE CHEVALIER T et al.: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a Phase II study. J. Clin. Oncol. (2003) 21:349-354.
   PubMed Web of Science ®Google Scholar
• VAN MEERBEECK P, GAAFAR R, MANEGOLD C et al.: Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. (2005) 23:6881-6889.
   PubMed Web of Science ®Google Scholar
• VOGELZANG NJ, GOUTSOU M, CORSON JM et al.: Carboplatin in malignant mesothelioma: a Phase II study of the Cancer and Leukaemia Group B. Cancer Chemother. Pharmacol. (1990) 27:239-242.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, CHEN V, SHIH C et al.: Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. (2000) 6:1016-1023.
   PubMed Web of Science ®Google Scholar
• HUGHES A, CALVERT P, AZZABI A et al.: Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2002) 20:3533-3544.
   PubMed Web of Science ®Google Scholar
• CERESOLI GL, ZUCALI PA, FAVARETTO AG et al.: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. (2006) 24:1443-1448.
   PubMed Web of Science ®Google Scholar
• FENNELL D, STEELE J, SHEAFF M et al.: Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Proceedings of the 11th World Conference on Lung Cancer. Barcelona, Spain (2005):P-397.
   Google Scholar
• MUERS MF, RUDD RM, O’BRIEN ME et al.: BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax (2004) 59:144-148.
   PubMed Web of Science ®Google Scholar
• O’BRIEN MER, WATKINS D, RYAN C et al.: A randomized trial in malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial. Ann. Oncol. (2006) 17:270-275.
   PubMed Web of Science ®Google Scholar
• SCHUTTE W, BLAKENBURG T, LAUERWALD K et al.: A multicenter Phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin. Lung Cancer (2003) 4:294-297.
   PubMedGoogle Scholar
• BOYAR MS, HESDORFFER M, TAUB RN: Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma. Proceedings of 42nd the ASCO Annual Meeting. Atlanta, GA, USA (2006):17133.
   Google Scholar
• TALBOT D, MARGERY J, DABUIS G et al.: Interim results of the Phase II study of vinflunine (VFL) in malignant pleural mesothelioma (MPM). Proceedings of 41st the ASCO Annual Meeting. Orlando, FL, USA (2005):7171.
   Google Scholar
• DESTRO A, CERESOLI GL, FALLENI M et al.: EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer (2006) 51(2):207-215.
   PubMed Web of Science ®Google Scholar
• EDWARDS JG, SWINSON DE, JONES JL, WALLER DA, O’BYRNE KJ: EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer (2006) 54(3):399-407.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
   PubMed Web of Science ®Google Scholar
• LIU Z, KLOMINEK J: Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine-kinase inhibitors. Neoplasia (2004) 6:705-712.
   PubMed Web of Science ®Google Scholar
• GOVINDAN R, KRATZKE RA, HERNDON JE et al.: On behalf of the Cancer and Leukemia Group B: Gefitinib in patients with malignant mesothelioma: a Phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. (2005) 11:2300-2304.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1:27-31.
   PubMed Web of Science ®Google Scholar
• O’BYRNE KJ, EDWARDS JG, WALLER DA: Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer (2004) 45(S1):45-48.
   PubMed Web of Science ®Google Scholar
• KUMAR-SINGH S, VERMEULEN PB, WEYLER J et al.: Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J. Pathol. (1997) 182:211-216.
   PubMed Web of Science ®Google Scholar
• OHTA Y, SHRIDHAR V, BRIGHT RK et al.: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer (1999) 81(1):54-61.
   PubMed Web of Science ®Google Scholar
• MASOOD R, KUNDRA A, ZHU S et al.: Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer (2003) 104:603-610.
   PubMed Web of Science ®Google Scholar
• KINDLER HL, KARRISON T, LU C et al.: A multicenter, double-blind, placebo-controlled randomized Phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proceedings of 42nd the ASCO Annual Meeting. Atlanta, GA, USA (2006):7019.
   Google Scholar
• FINE HA, FIGG WD, JAECKLE K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. (2000) 18:708-715.
   PubMed Web of Science ®Google Scholar
• PAVLAKIS N, ABRAHAM R, HARVIE R: Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma (MM): interim results of two parallel non randomised Phase II studies. Proceedings of the 10th World Conference on Lung Cancer. Vancouver, Canada (2003):O-26.
   Google Scholar
• BAAS P, BOOGERD W, DALESIO O, HARINGHUIZEN A, CUSTERS F, VAN ZANDWIJK N: Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer (2005) 48(2):291-296.
   PubMed Web of Science ®Google Scholar
• JAHAN TM, GU L, WANG X et al.: Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a Phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proceedings of the 42nd ASCO Annual Meeting. Atlanta, GA, USA (2006):7081.
   Google Scholar
• YEE D: Are the insulin-like growth factors relevant to cancer? Growth Horm. IGF Res. (2001) 11:339-345.
   PubMed Web of Science ®Google Scholar
• HOANG CD, D’CUNHA J, KRATZKE MG et al.: Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest (2004) 125:1843-1852.
   PubMed Web of Science ®Google Scholar
• SCOTLANDI K, MANARA MC, NICOLETTI G et al.: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. (2005) 65:3868-3876.
   PubMed Web of Science ®Google Scholar
• KELLY WK, O’CONNOR OA, KRUG L et al.: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. (2005) 23:3923-3931.
   PubMed Web of Science ®Google Scholar
• O’CONNOR OA, HEANEY ML, SCHWARTZ L et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. (2006) 24(1):166-173.
   PubMed Web of Science ®Google Scholar
• KRUG LM, CURLEY T, SCHWARTZ L et al.: Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer (2006) 7(4):257-261.
   PubMed Web of Science ®Google Scholar
• HORI Y, HORI H, YAMADA Y et al.: The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int. J. Cancer (1998) 75:51-56.
   PubMed Web of Science ®Google Scholar
• ILLEI PB, RUSCH VW, ZAKOWSKI MF, LADANYI M: Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. (2003) 9(6):2108-2113.
   PubMed Web of Science ®Google Scholar
• CHATTOPADHYAY S, ZHAO R, TSAI E, SCHRAMM VL, GOLDMAN ID: The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol. Cancer Ther. (2006) 5(10):2549-2555.
   PubMed Web of Science ®Google Scholar
• YANG CT, YOU L, YEH CC et al.: Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. (2000) 92:636-641.
   PubMed Web of Science ®Google Scholar
• FLYNN J, BERG RW, WONG T et al.: Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol. Cancer Ther. (2006) 5(6):1423-1433.
   PubMed Web of Science ®Google Scholar
• KOSURI KV, OTTERSON G: The role of methylation leading to capecitabine resistant malignant mesothelioma. Proceedings of 42nd the ASCO Annual Meeting. Atlanta, GA, USA (2006):17105.
   Google Scholar
• WEDER W, KESTENHOLZ P, TAVERNA C et al.: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. (2004) 22:3451-3457.
   PubMed Web of Science ®Google Scholar
• RUSCH VW: Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J. Clin. Oncol. (2003) 21:2629-2630.
   PubMed Web of Science ®Google Scholar
• POTTI A, MUKHERJEE S, PETERSEN R et al.: A genomic strategy to refine prognosis in early-stage non–small-cell lung cancer. N. Engl. J. Med. (2006) 355:570-580.
   PubMed Web of Science ®Google Scholar
• GORDON GJ, ROCKWELL GN, GODFREY PA et al.: Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. (2005) 11:4406-4414.
   PubMed Web of Science ®Google Scholar
• PASS HI, LIU Z, WALI A et al.: Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. (2004) 10:849-859.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, WIEWRODT R, MALDEN LD et al.: Gene expression profiling of malignant mesothelioma. Clin. Cancer Res. (2003) 9:3080-3097.
   PubMed Web of Science ®Google Scholar
• LÓPEZ-RÍOS F, CHUAI S, FLORES R et al.: Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and p16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. (2006) 66:2970-2979.
   PubMed Web of Science ®Google Scholar